



## **Virbac to acquire veterinary assets from Pfizer in Australia**

CARROS, France – January 12, 2010

Virbac announces that it has entered into an agreement with Pfizer Inc. to acquire certain veterinary products and related assets, including a manufacturing facility, in Australia. The Australian competition authorities require these assets to be divested by Pfizer in connection with its recent acquisition of Wyeth, including its Fort Dodge Animal Health business. Almost all the staff of the manufacturing facility along with certain other employees are expected to join Virbac's operations in its Australian affiliate, Virbac Australia.

Under the terms of the agreement, Virbac will acquire rights to a portfolio of livestock products historically marketed in Australia by Fort Dodge Animal Health for use in farm animals, primarily cattle and sheep. The portfolio includes parasiticides (80% of sales) and vaccines (20%) that achieved net sales of approximately 36 million Australian dollars in 2009. This new portfolio will perfectly fit and complement the current range of products that Virbac Australia is bringing to its customers.

This transaction is subject to the approval of the Australian Competition and Consumer Commission and other closing conditions.

VIRBAC : Passionate about Animal Health  
NYSE Euronext – Compartment B / ISIN : FR0000031577 / MNEMO : VIRP  
Corporate Finance : tél. 33 4 92 08 71 32  
E-mail : [finances@virbac.com](mailto:finances@virbac.com) – Website : [www.virbac.com](http://www.virbac.com)